Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand
Authors:
- 1 July 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (19) , 4424-4429
Abstract
Purpose: Onycholysis and skin toxicity occur in approximately 30% of patients treated with docetaxel. We investigated the efficacy and safety of an Elasto-Gel (84400 APT Cedex, Akromed, France) frozen glove (FG) for the prevention of docetaxel-induced onycholysis and skin toxicity. Patients and Methods: Patients receiving docetaxel 75 mg/m2 alone or in combination chemotherapy were eligible for this case-control study. Each patient wore an FG for a total of 90 minutes on the right hand. The left hand was not protected and acted as the control. Onycholysis and skin toxicity were assessed at each cycle by National Cancer Institute Common Toxicity Criteria and documented by photography. Wilcoxon matched-pairs rank test was used. Results: Between August 2002 and September 2003, 45 patients were evaluated. Onycholysis and skin toxicity were significantly lower in the FG-protected hand compared with the control hand (P = .0001). Onycholysis was grade (G) 0 in 89% v 49% and G1 to 2 in 11% v 51% for the FG-protected hand and the control hand, respectively. Skin toxicity was G0 in 73% v 41% and G1 to 2 in 27% v 59% for the FG-protected and the control hand, respectively. Median time to nail and skin toxicity occurrence was not significantly different between the FG-protected and the control hand, respectively (106 v 58 days for nail toxicity; 57 v 58 days for skin toxicity). Five patients (11%) experienced discomfort due to cold intolerance. Conclusion: FG significantly reduces the nail and skin toxicity associated with docetaxel and provides a new tool in supportive care management to improve a patient's quality of life.Keywords
This publication has 23 references indexed in Scilit:
- Preclinical Pharmacology of the Taxanes: Implications of the DifferencesThe Oncologist, 2004
- Cutaneous Hand and Foot Toxicity Associated With Cancer ChemotherapyAmerican Journal of Clinical Oncology, 2003
- Managing taxane toxicitiesSupportive Care in Cancer, 2003
- Taxane-induced nail changes: incidence, clinical presentationand outcomeAnnals of Oncology, 2003
- Subungual abscess: a new ungual side-effect related to docetaxel therapyBritish Journal of Dermatology, 2000
- Antineoplastic Therapy???Induced Palmar Plantar Erythrodysesthesia (???Hand-Foot???) SyndromeAmerican Journal of Clinical Dermatology, 2000
- Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell DeathJournal of Clinical Oncology, 1999
- Drug-Induced Nail DisordersDrug Safety, 1999
- 5-Fluorouracil and mitomycin-C in colorectal cancer: Unacceptable conclusionAnnals of Oncology, 1998
- Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.Journal of Clinical Oncology, 1994